These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 27496866)

  • 21. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
    Khushalani NI; Ott PA; Ferris RL; Cascone T; Schadendorf D; Le DT; Sharma MR; Barlesi F; Sharfman W; Luke JJ; Melero I; Lathers D; Neely J; Suryawanshi S; Sanyal A; Holloway JL; Suryawanshi R; Ely S; Segal NH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
    Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
    Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
    Taylor RJ; Saloura V; Jain A; Goloubeva O; Wong S; Kronsberg S; Nagilla M; Silpino L; de Souza J; Seiwert T; Vokes E; Villaflor V; Cohen EE
    Cancer Immunol Res; 2015 May; 3(5):567-74. PubMed ID: 25769300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
    Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
    Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
    Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
    Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
    Correale P; Botta C; Cusi MG; Del Vecchio MT; De Santi MM; Gori Savellini G; Bestoso E; Apollinari S; Mannucci S; Marra M; Abbruzzese A; Aquino A; Turriziani M; Bonmassar L; Caraglia M; Tagliaferri P
    Int J Cancer; 2012 Apr; 130(7):1577-89. PubMed ID: 21618510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
    Chester C; Sanmamed MF; Wang J; Melero I
    Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
    Maniar A; Zhang X; Lin W; Gastman BR; Pauza CD; Strome SE; Chapoval AI
    Blood; 2010 Sep; 116(10):1726-33. PubMed ID: 20519625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.
    Sallin MA; Zhang X; So EC; Burch E; Cai L; Lin W; Chapoval AI; Strome SE
    Cancer Immunol Immunother; 2014 Sep; 63(9):947-58. PubMed ID: 24927849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 35. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
    Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
    Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.
    Lin W; Voskens CJ; Zhang X; Schindler DG; Wood A; Burch E; Wei Y; Chen L; Tian G; Tamada K; Wang LX; Schulze DH; Mann D; Strome SE
    Blood; 2008 Aug; 112(3):699-707. PubMed ID: 18519814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
    Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
    Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
    Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
    J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.